Encorafenib, sold under the brand name Braftovi, is a medication for the treatment of certain melanoma cancers. It is a small molecule BRAF inhibitor that targets key enzymes in the MAPK signaling pathway. Read More
Encora, a global next-gen product engineering provider, today announced its offices in India have been named among the top 25 workplaces by Great Place to Work® India in the Information Technology (IT) and Information Technology and Business Process ...